Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 10/20 | 0.39 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.36 |
| ▸ | TACR2 | P21452 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.35 |
| ▸ | CDC25B | P30305 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13651137 | 1.00 | SLC5A2 (0.39) | SLC5A2SLC5A1TACR2NT5EPTPN1 | |
| SCHEMBL1457374 | 0.85 | PTPN1 (0.44) | SLC5A2SLC5A1TACR2PTPN1CDC25B | |
| SCHEMBL13947257 | 0.85 | PTPN1 (0.44) | SLC5A2SLC5A1TACR2PTPN1CDC25B | |
| SCHEMBL13201198 | 0.82 | DRD2 (0.42) | TACR2NT5EPTPN1CDC25BCA1 | |
| SCHEMBL12425693 | 0.82 | DRD2 (0.42) | TACR2NT5EPTPN1CDC25BCA1 | |
| SCHEMBL1457588 | 0.81 | TACR2 (0.33) | SLC5A2SLC5A1TACR2NT5EPTPN1 | |
| SCHEMBL20141043 | 0.81 | SLC5A2 (0.41) | SLC5A2SLC5A1NT5EPTPN1CDC25B | |
| SCHEMBL20139702 | 0.80 | SLC5A2 (0.53) | SLC5A2SLC5A1TACR2 | |
| SCHEMBL1457455 | 0.80 | SLC5A2 (0.47) | SLC5A2SLC5A1 | |
| SCHEMBL13947258 | 0.80 | SLC5A2 (0.47) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140046046-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140046046-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140046046-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20120296080-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20120296080-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20120296080-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| EP-1730131-B1 | GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2012-05-09 | — | — | EP | disclosed |
| EP-1730131-B1 | GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2012-05-09 | — | — | EP | disclosed |
| EP-2360165-A2 | GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | Boehringer Ingelheim International GmbH (DE) | 2011-08-24 | — | — | EP | disclosed |
| EP-2360164-A2 | GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | Boehringer Ingelheim International GmbH (DE) | 2011-08-24 | — | — | EP | disclosed |
| US-7579449-B2 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-7579449-B2 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-20090023913-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023913-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023913-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-22 | — | — | US | disclosed |
| WO-2007014894-A2 | GLUCOPYRANOSYL-SUBSTITUTED ( (HETERO) CYCLOALYKLETHYNYL-BENZYL) -BENZENE DERIVATIVES AND USE THEREOF AS SODIUM-DEPENDENT GLUCOSE COTRANSPORTER (SGLT) INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027092-A1 | Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-01 | — | — | US | disclosed |
| US-20070027092-A1 | Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-01 | — | — | US | disclosed |
| US-20060189548-A1 | Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-24 | — | — | US | disclosed |
| US-20050209166-A1 | Metabolic disorders like diabetes; inhibits sodium-dependent glucose cotransporter; 1-chloro-2-(4-cyclopentyloxybenzyl)-4-( beta -D-glucopyranos-1-yl)-benzene | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027092-A1 | Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | UGGT1, GPR119, UGT2B7 | SLC5A2 7/4885SLC5A1 6/4885TACR2 2146/4885 |
| US-20090023913-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | UGGT1, G6PD, SLC5A1 | SLC5A2 5/4885SLC5A1 3/4885TACR2 3368/4885 |
| US-20060189548-A1 | Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | UGGT1, UGT2B7, GPR119 | SLC5A2 5/4885SLC5A1 9/4885TACR2 3222/4885 |
| US-20050209166-A1 | Metabolic disorders like diabetes; inhibits sodium-dependent glucose cotransporter; 1-chloro-2-(4-cyclopentyloxybenzyl)-4-( beta -D-glucopyranos-1-yl)-benzene | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885TACR2 1406/4885 |
| US-20120296080-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | UGGT1, G6PD, G6PC1 | SLC5A2 7/4885SLC5A1 5/4885TACR2 3483/4885 |
| US-20140046046-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | UGGT1, G6PD, SLC5A1 | SLC5A2 5/4885SLC5A1 3/4885TACR2 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.